AB-Biotics signed a distribution contract with Scienta Farma for the marketing of genetic test for treatment of neuropsychiatric patients Neurofarmagen, which is produced by AB-Biotics. The agreement establishes that Scienta Farma will have the exclusive rights to distribute Neurofarmagen in Mexico, where roughly 33 million people are affected by mental diseases each year. The test is used to identify the best treatment for different mental health pathologies, including depression, schizophrenia, bipolar disorder, and epilepsy.

The test works on the basis that the response to the treatment of each pathology can be influenced by up to 85% of genetic factors.